<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638052</url>
  </required_header>
  <id_info>
    <org_study_id>CMH IRB 2005-12645</org_study_id>
    <nct_id>NCT01638052</nct_id>
  </id_info>
  <brief_title>Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery</brief_title>
  <official_title>Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery: Does the Addition of Clonidine Increase the Duration of Postoperative Analgesia?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators goal is to determine the efficacy and duration of analgesia with the&#xD;
      addition of Clonidine, an alpha-2 agonist, to local anesthetic blockade using bupivacaine, of&#xD;
      the great auricular nerve in children undergoing tympanomastoid surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surgical anesthesia during the operative procedure will be maintained using volatile&#xD;
      anesthetics. No prophylactic dexamethasone or ondansetron would be provided to any patients&#xD;
      in either group. Anesthesia will be discontinued at the end of the procedure and the patient&#xD;
      will be extubated once standard extubation criteria have been met. Patients will be then&#xD;
      taken to the postoperative recovery room where they will be evaluated for pain and discomfort&#xD;
      by a blinded observer using the CHIPPS (Children and Infants Postoperative Pain Scale). If&#xD;
      two consecutive pain scores at 5 minute intervals is &gt;6, they will be rescued with&#xD;
      incremental doses of 0.05 mg/kg of intravenous morphine required to reach a score of &lt;6. The&#xD;
      number of rescue doses as well as the pain scores will be documented. These patients will be&#xD;
      also observed for the presence of nausea/vomiting. Any patient who vomits more than two times&#xD;
      will be rescued with ondansetron 0.1 mg/kg intravenously. All patients will be continued to&#xD;
      be evaluated in the 23 hour unit. Pain and side effects will be assessed for the next 6 hours&#xD;
      or until discharge from the 23 hour observation facility. Standard doses of acetaminophen&#xD;
      with codeine will be provided for pain relief in the 23 hour observational unit, as well as&#xD;
      on discharge. The number of doses of acetaminophen with codeine will be recorded. Time to&#xD;
      discharge from the hospital will also be noted. A questionnaire designed to address&#xD;
      parent/patient satisfaction will be utilized and will allude to the need for rescue analgesia&#xD;
      and the need for any other additional analgesics provided. The use of any additional rescue&#xD;
      pain medication will be provided to the families at the time of discharge. A follow-up phone&#xD;
      call will be made in 24 hours to note the information provided on the questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Observer-Rated Patient Pain Scores</measure>
    <time_frame>60 minutes</time_frame>
    <description>Patients will be observed with behaviors rated at regular time intervals using the CHIPPS (Children and Infants Postoperative Pain Scale) pain survey. The CHIPPS scale values range from a minimum of 0 (no pain, better outcome) to a maximum of 10 (worst pain, worse outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nausea/Vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of nausea/vomiting during 24 hour observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Use of Rescue Analgesic Medication in the Initial 24 Hours Postoperatively</measure>
    <time_frame>24 hours</time_frame>
    <description>Count of participants who will require use of rescue analgesic medication in the initial 24 hours postoperatively as recorded in the hospital or by parents at home following discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Tympanomastoid Surgery</condition>
  <condition>Cochlear Implant</condition>
  <condition>Mastoidectomy</condition>
  <condition>Cholesteatoma</condition>
  <arm_group>
    <arm_group_label>0.25% Bupivacaine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is our standard of care concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% Bupivacaine + Clonidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25% Bupivacaine + Clonidine</intervention_name>
    <description>Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
    <arm_group_label>0.25% Bupivacaine + Clonidine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 1-18 years&#xD;
&#xD;
          -  tympanomastoid surgery (cochlear implant, mastoidectomy, cholesteatoma surgery)&#xD;
&#xD;
          -  ASA I, II&#xD;
&#xD;
          -  informed consent and assent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergic to local anesthestic&#xD;
&#xD;
          -  taking chronic aspirin or Ibuprofen therapy&#xD;
&#xD;
          -  ASA IV&#xD;
&#xD;
          -  history of clinically important renal, hepatic, respiratory, cardiac, or neurological&#xD;
             conditions&#xD;
&#xD;
          -  Patients who have cardiovascular surgery other than an atrial septal defect or a&#xD;
             ventricular septal defect, or who have undergone complete corrective intracardiac&#xD;
             repair of congenital heart disease.&#xD;
&#xD;
          -  Informed consent not obtained&#xD;
&#xD;
          -  Patients expected to receive dexamethasone or ondansetron intra-operative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santhanam Suresh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Suresh S, Barcelona SL, Young NM, Seligman I, Heffner CL, Coté CJ. Postoperative pain relief in children undergoing tympanomastoid surgery: is a regional block better than opioids? Anesth Analg. 2002 Apr;94(4):859-62, table of contents.</citation>
    <PMID>11916785</PMID>
  </reference>
  <reference>
    <citation>Wheeler M, Patel A, Suresh S, Roth AG, Birmingham PK, Heffner CL, Coté CJ. The addition of clonidine 2 microg.kg-1 does not enhance the postoperative analgesia of a caudal block using 0.125% bupivacaine and epinephrine 1:200,000 in children: a prospective, double-blind, randomized study. Paediatr Anaesth. 2005 Jun;15(6):476-83.</citation>
    <PMID>15910348</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <results_first_submitted>December 23, 2020</results_first_submitted>
  <results_first_submitted_qc>June 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tympanomastoid Surgery</keyword>
  <keyword>Cochlear Implant</keyword>
  <keyword>Mastoidectomy</keyword>
  <keyword>Cholesteatoma</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Clonidine</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Greater Auricular Nerve Block</keyword>
  <keyword>Regional Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholesteatoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.25% Bupivacaine</title>
          <description>This is our standard of care concentration</description>
        </group>
        <group group_id="P2">
          <title>0.25% Bupivacaine + Clonidine</title>
          <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.25% Bupivacaine</title>
          <description>This is our standard of care concentration</description>
        </group>
        <group group_id="B2">
          <title>0.25% Bupivacaine + Clonidine</title>
          <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.9" lower_limit="1" upper_limit="17"/>
                    <measurement group_id="B2" value="7.5" lower_limit="1" upper_limit="18"/>
                    <measurement group_id="B3" value="7.2" lower_limit="1" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Observer-Rated Patient Pain Scores</title>
        <description>Patients will be observed with behaviors rated at regular time intervals using the CHIPPS (Children and Infants Postoperative Pain Scale) pain survey. The CHIPPS scale values range from a minimum of 0 (no pain, better outcome) to a maximum of 10 (worst pain, worse outcome).</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.25% Bupivacaine</title>
            <description>This is our standard of care concentration</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine + Clonidine</title>
            <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Average Observer-Rated Patient Pain Scores</title>
          <description>Patients will be observed with behaviors rated at regular time intervals using the CHIPPS (Children and Infants Postoperative Pain Scale) pain survey. The CHIPPS scale values range from a minimum of 0 (no pain, better outcome) to a maximum of 10 (worst pain, worse outcome).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1.05"/>
                    <measurement group_id="O2" value="1.9" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nausea/Vomiting</title>
        <description>Incidence of nausea/vomiting during 24 hour observation</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.25% Bupivacaine</title>
            <description>This is our standard of care concentration</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine + Clonidine</title>
            <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nausea/Vomiting</title>
          <description>Incidence of nausea/vomiting during 24 hour observation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Use of Rescue Analgesic Medication in the Initial 24 Hours Postoperatively</title>
        <description>Count of participants who will require use of rescue analgesic medication in the initial 24 hours postoperatively as recorded in the hospital or by parents at home following discharge.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.25% Bupivacaine</title>
            <description>This is our standard of care concentration</description>
          </group>
          <group group_id="O2">
            <title>0.25% Bupivacaine + Clonidine</title>
            <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Use of Rescue Analgesic Medication in the Initial 24 Hours Postoperatively</title>
          <description>Count of participants who will require use of rescue analgesic medication in the initial 24 hours postoperatively as recorded in the hospital or by parents at home following discharge.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.25% Bupivacaine</title>
          <description>This is our standard of care concentration</description>
        </group>
        <group group_id="E2">
          <title>0.25% Bupivacaine + Clonidine</title>
          <description>These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.&#xD;
0.25% Bupivacaine + Clonidine : Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Santhanam Suresh, MD</name_or_title>
      <organization>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</organization>
      <phone>312-227-5147</phone>
      <email>SSuresh@luriechildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

